PhRMA comments to administration on Medicare Part D proposed rule

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the CMS proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and...
Read More
ICYMI: New study reinforces dangers of proposed IPI model

Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in...
Read More
Groups sound the alarm on administration’s new Part B proposal

Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...
Read More
4 things you need to know about the administration’s latest Part B proposal

The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....
Read More
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in...
Read More
How much do you know about Medicare Part B?

In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...
Read More
ICER’s budget impact threshold: Sounding a false alarm on affordability and access

If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More
Event next week: Supporting the next generation of lifesaving medicines

The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...
Read More
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More